Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 226256-56-0 Chemical Structure| 226256-56-0

Structure of Cinacalcet
CAS No.: 226256-56-0

Chemical Structure| 226256-56-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cinacalcet (AMG 073) is an orally active, allosteric agonist of the calcium receptor (CaR), used for cardiovascular disease research.

Synonyms: AMG 073; Sensipar; Cin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cinacalcet

CAS No. :226256-56-0
Formula : C22H22F3N
M.W : 357.41
SMILES Code : FC(C1=CC(CCCN[C@@H](C2=C3C=CC=CC3=CC=C2)C)=CC=C1)(F)F
Synonyms :
AMG 073; Sensipar; Cin
MDL No. :MFCD09840270

Safety of Cinacalcet

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H315-H319-H360
Precautionary Statements:P201-P202-P264-P270-P280-P301+P312-P302+P352-P305+P351+P338-P308+P313-P321-P330-P332+P313-P337+P313-P362+P364-P405-P501
Class:6.1
UN#:2810
Packing Group:

Related Pathways of Cinacalcet

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Enterococcus faecalis (LRE 16C352) 12.5 mg/mL 16 hours Cinacalcet at concentrations above 12.5 mg/mL could completely inhibit growth of planktonic cells PMC10074155
Enterococcus faecalis (E. faecalis 16C51) 12.5 mg/mL 16 hours Cinacalcet at concentrations above 12.5 mg/mL could completely inhibit growth of planktonic cells PMC10074155
Staphylococcus aureus (MRSA YUSA145) 12.5 mg/mL 16 hours Cinacalcet at concentrations above 12.5 mg/mL could completely inhibit growth of planktonic cells PMC10074155
Staphylococcus aureus (MSSA CHS101) 12.5 mg/mL 16 hours Cinacalcet at concentrations above 12.5 mg/mL could completely inhibit growth of planktonic cells PMC10074155
Osteoclasts 400 nM 18 hours Cinacalcet significantly reduced the bone resorption area and increased Wnt10b expression and release from osteoclasts. PMC6600662
MDCK cells 30 μM 20 minutes Cinacalcet inhibited forskolin-induced cAMP elevation by 60%, and its effect was completely reversed by IBMX PMC10922239
MDCK cells 30 μM 20 minutes Cinacalcet inhibited forskolin-induced Cl− secretion and CFTR activity, reducing short-circuit current changes by ~70% PMC10922239
Human intestinal T84 cells 30 μM 20 minutes Cinacalcet pretreatment inhibited all 3 components of forskolin and cholera toxin-induced secretory short-circuit currents (Isc) (CFTR, Clc-2, and K+ channels) by ∼75%. PMC11071643
HBE cells 30 μM 20 minutes Cinacalcet pretreatment significantly inhibited CFTR-mediated Cl- secretion but had no significant effect on ENaC or CaCC activities. PMC7934922
FRT cells 30 μM 20 minutes Cinacalcet pretreatment did not affect CFTR-mediated Cl- conductance, indicating its inhibitory effect on CFTR is dependent on CaSR activation. PMC7934922
T84 cells 10 μM and 30 μM 20 minutes Cinacalcet significantly inhibited forskolin-induced Cl- secretion, reducing ISC increase by approximately 50% and 85%, respectively. PMC7934922
HEK293 cells 10 nM 20 minutes To evaluate the effect of Cinacalcet on signaling in Gα11 Asp195Gly mutant cells, results showed that 10 nM Cinacalcet corrected the signaling abnormalities in mutant cells. PMC5846897
Bone marrow-derived macrophages (BMDMs) 0.1, 1, 5 μM 24 hours Cinacalcet significantly reduced the TNFα-induced mRNA expression and secretion levels of inflammatory cytokines IL-1β and IL-6. PMC8645985
RAW264.7 cells 0.1, 1, 5 μM 24 hours Cinacalcet significantly reduced the TNFα-induced mRNA expression and secretion levels of inflammatory cytokines IL-1β and IL-6. PMC8645985
HEK293 cells 100nM 30 minutes To evaluate the effect of Cinacalcet on intracellular calcium signaling in HEK293 cells expressing wild-type and mutant CaSR, results showed that Cinacalcet could correct the abnormal intracellular calcium signaling caused by Ile555Thr mutation. PMC7615553
Human primary ADPKD cells 3 μM 6 days Cinacalcet inhibited forskolin-induced cyst enlargement by 60% and reduced cell proliferation PMC10922239
MDCK cells 1-10 μM 6 days Cinacalcet concentration-dependently reduced cell proliferation, cyst formation and cyst enlargement by up to 50% without affecting cell viability PMC10922239
Cells expressing the calcium-sensing receptor and AP2-sigma mutants 10 nM Corrected the abnormal intracellular calcium signaling and MAPK responses to extracellular calcium PMC4972445

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice DSS-induced colitis model Oral gavage 0.1, 1, 10 mg/kg Daily administration until the end of the experiment Cinacalcet significantly reduced the disease activity index score, prevented colon shortening, diminished inflammatory cell infiltration, and protected the structural integrity of the intestinal wall. Additionally, Cinacalcet reduced the production of inflammatory cytokines TNFα, IL-1β, and IL-6 in the colon and sera of mice with DSS-induced colitis. PMC8645985
Mice Intestinal closed loop models of cholera and traveler’s diarrhea Intraperitoneal injection 1, 10 and 30 mg/kg Single dose, lasting 3 hours Cinacalcet at 30 mg/kg significantly inhibited intestinal fluid accumulation induced by cholera toxin and STa toxin, reducing fluid accumulation by approximately 75% and 60%, respectively. PMC7934922
Mice (BALB/c and C57BL/6J) Pneumonia infection model and deep-seated infection model Intraperitoneal injection 10 mg/kg (pneumonia model) and 40 mg/kg (deep-seated infection model) Every 24 hours for 2 days Cinacalcet exhibited high anti-infective efficacy in vivo, comparable to vancomycin PMC10074155
C57BL/6 mice 5/6 nephrectomy CKD model Oral gavage 10 mg/kg/day Once daily for 4 weeks Cinacalcet significantly decreased serum PTH levels, reduced cortical porosity, and improved bone strength and stiffness. PMC6600662
Mice ADPKD mouse model Subcutaneous injection 20 mg/kg/day Once daily for 7 days Cinacalcet treatment reduced renal cyst enlargement by 20%, decreased kidney/body weight ratio and serum BUN PMC10922239
Mice Cholera toxin-induced secretory diarrhea model Oral 30 mg/kg Single dose, evaluated at 20 hours Cinacalcet inhibited forskolin-induced secretory Isc by ~60% in wild-type mice and had no antisecretory effect in intestinal epithelia-specific Casr knockout mice. In the suckling mouse model of cholera induced by oral cholera toxin, a single oral dose of cinacalcet reduced intestinal fluid accumulation by ~55% at 20 hours. PMC11071643
Mice Gna11+/195G and Gna11195G/195G mice Oral 30 mg/kg Single dose, plasma samples collected at 0, 1, 2, 4, 6, and 24 hours post-dose To evaluate the effect of Cinacalcet on hypercalcemia and PTH levels in Gna11 mutant mice, results showed that Cinacalcet significantly reduced plasma calcium and PTH concentrations. PMC5846897

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02464072 Hyperparathyroidism, Secondary Not Applicable Active, not recruiting July 2019 Brazil ... More >> University of Sao Paulo General Hospital Sao Paulo, SP, Brazil Less <<
NCT01073462 - Completed - -
NCT01073462 - Completed - Austria ... More >> Site Reference ID/Investigator# 27447 Graz, Austria, 8010 Site Reference ID/Investigator# 49182 Graz, Austria, 8020 Site Reference ID/Investigator# 27483 Graz, Austria, 80360 Site Reference ID/Investigator# 52742 Graz, Austria, 8052 Site Reference ID/Investigator# 27487 Innsbruck, Austria, 6020 Site Reference ID/Investigator# 36983 Linz, Austria, 4010 Site Reference ID/Investigator# 27484 Linz, Austria, 4020 Site Reference ID/Investigator# 27485 Rottenmann, Austria, 8786 Site Reference ID/Investigator# 27446 Vienna, Austria, 1030 Site Reference ID/Investigator# 53469 Vienna, Austria, 1090 Site Reference ID/Investigator# 27482 Vienna, Austria, 1130 Site Reference ID/Investigator# 10981 Vienna, Austria, 1220 Less <<
NCT02102204 Hyperparathyroidism, Secondary Phase 3 Completed - -
NCT02102204 - Completed - -
NCT03527511 - Recruiting May 14, 2020 France ... More >> Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant - Bron. Recruiting Bron, France, 69677 Contact: Justine BACCHETTA, Pr    04 27 85 61 30 ext +33    justine.bacchetta@chu-lyon.fr    Principal Investigator: Justine BACCHETTA, Pr          Sub-Investigator: Bruno RANCHIN, Dr          Sub-Investigator: Anne-Laure SELIER-LECLERC, Dr          Sub-Investigator: Aurélia BERTHOLET-THOMAS, Dr          Sub-Investigator: Elodie CHEYSSAC, Dr          Sub-Investigator: Corentin TANNE, Dr Less <<
NCT01717989 - Completed - -
NCT01421407 Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Parathyroid Hyperplasia Less << Not Applicable Withdrawn - Italy ... More >> Ospedale generale regionale "Miulli" Acquaviva delle Fonti, Italy, 70021 Ospedale Maggiore Policlinico Mangiagalli e Regina Elena Milano, Italy, 20122 Spain Hospital Universitario Marquès de Valdecilla Santander, Cantabria, Spain, 39008 Less <<
NCT03603444 - Completed - Italy ... More >> Azienda Ospedaliero - Universitaria di Modena Modena, Italy, 41124 Less <<
NCT00189501 - Completed - -
NCT01717989 - Completed - -
NCT00110656 - Completed - -
NCT02273570 Hyperparathyroidism, Secondary Not Applicable Unknown March 2017 Italy ... More >> Azienda Ospedaliera Sant'Anna Recruiting San Fermo della battaglia (CO), Italy, 22020 Contact: Simona Urbano    +39.031.585.8947    comitato.etica@hsacomo.org    Principal Investigator: Antonio Bellasi, MD          Principal Investigator: Claudio Minoretti, MD Less <<
NCT00042432 Secondary Hyperparathyroidism ... More >> Chronic Renal Insufficiency Less << Phase 2 Completed - -
NCT01011699 Chronic Renal Failure ... More >> Hemodialysis Less << Phase 3 Terminated(Financial problem) - France ... More >> Centre Hospitalier Général Soissons, Aisne, France, 02009 Centre Hospitalier Lisieux, Calvados, France, 14100 ALURAD Limoges, Limousin, France, 87042 Centre Hospitalier Universitaire Reims, Marne, France, 51092 Association Régionale Promotion Dialyse à domicile (ARPDD) Reims, Marne, France Association pour le Développement de l'Hémodialyse Hénin-Beaumont, Nord-Pas de Calais, France, 62110 Polyclinique de la Louvière Lille, Nord, France, 59000 CHRU Lille, Nord, France, 59037 Hôpital Victor Provo Roubaix, Nord, France, 59056 Centre Hospitalier Général Valenciennes, Nord, France, 59322 Centre Hospitalier Général Beauvais, Oise, France, 60000 Clinique Saint Côme Compiegne, Oise, France, 60200 Centre Hospitalier Général Creil, Oise, France, 60100 Clinique du Bois Bernard Bois Bernard, Pas de calais, France, 62320 Centre Hospitalier Boulogne sur mer, Pas de calais, France, 62200 Centre Hospital-Universitaire d'Amiens Amiens, Picardie, France, 80054 Clinique de l'Europe Rouen, Seine maritime, France, 76040 Centre Hospitalier Cambrai, France, 59407 Less <<
NCT00037518 Hyperparathyroidism|Parathyroi... More >>d Neoplasms Less << PHASE4 COMPLETED - -
NCT02216656 Secondary Hyperparathyroidism Phase 2 Completed - Japan ... More >> For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Tokyo, Japan Less <<
NCT02440581 Kidney Failure, Chronic Not Applicable Recruiting June 2020 United States, Kentucky ... More >> University of Kentucky Recruiting Lexington, Kentucky, United States, 40536 Contact: Nedda Hughes, PA    859-218-1509    nkhugh1@uky.edu    Contact: Tara Spach    859-323-2672    tara.spach@uky.edu Less <<
NCT00656032 End Stage Renal Disease Phase 2 Completed - United States, Tennessee ... More >> Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 Less <<
NCT00037635 Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << Phase 3 Completed - -
NCT00395902 - Completed - -
NCT01100723 Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << Phase 4 Completed - United States, Virginia ... More >> Lynchburg Nephrology Associates, P.L.L.C. Lynchburg, Virginia, United States, 24501 Less <<
NCT00042432 - Completed - -
NCT02525796 Primary Hyperparathyroidism Phase 2 Phase 3 Recruiting December 2020 United States, Massachusetts ... More >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Molly Connors    617-732-5186 Less <<
NCT01932970 Hyperparathyroidism, Secondary Phase 3 Completed - -
NCT00325104 Hypercalcemia ... More >> Familial Primary Hyperparathyroidism Less << Phase 3 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT02133404 Secondary Hyperparathyroidism Phase 2 Completed - Japan ... More >> Chubu, Japan Chugoku, Japan Kanto, Japan Kyushu, Japan Shikoku, Japan Tohoku, Japan Less <<
NCT00042653 Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << Phase 3 Completed - -
NCT00132431 Kidney Disease|Secondary Hyper... More >>parathyroidism|Chronic Kidney Disease Less << PHASE4 COMPLETED 2025-07-05 -
NCT01932970 - Completed - -
NCT01599962 Memory Functions Phase 2 Completed - Switzerland ... More >> University of Basel, Division of Cognitive Neuroscience Basel, Switzerland, 4055 Less <<
NCT00110929 End Stage Renal Disease PHASE2 COMPLETED - -
NCT01573520 Hyperparathyroidism ... More >> Chronic Kidney Disease Less << Phase 4 Completed - Switzerland ... More >> Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, 1011 Less <<
NCT01100723 - Completed - -
NCT01748812 Osteomalacia Phase 1 Terminated - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00527085 Renal Osteodystrophy Phase 2 Completed - -
NCT00261950 Secondary Hyperparathyroidism Phase 2 Completed - -
NCT02227264 Primary Hyperparathyroidism Not Applicable Unknown December 2016 Sweden ... More >> Karolinska University Hospital Recruiting Stockholm, Sweden, 171 76 Contact: Inga-Lena Nilsson, Assoc.prof.       inga-lena.nilsson@ki.se Less <<
NCT00261950 - Completed - -
NCT00113945 End Stage Renal Disease PHASE2 COMPLETED - -
NCT00135304 Secondary Hyperparathyroidism Phase 4 Completed - -
NCT00110890 End Stage Renal Disease Phase 4 Completed - -
NCT00415584 Secondary Hyperparathyroidism ... More >> Hypercalcemia Less << Not Applicable Withdrawn(low enrollment) - United States, New York ... More >> Montefiore Medical Center Bronx, New York, United States, 10467 Less <<
NCT02549391 Secondary Hyperparathyroidism Phase 2 Phase 3 Completed - Japan ... More >> For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Tokyo, Japan Less <<
NCT00527267 Hyperparathyroidism Phase 3 Completed - -
NCT00110890 - Completed - -
NCT00446329 Secondary Hyperparathyroidism Phase 4 Terminated(due to financial pr... More >>oblems) Less << - Greece ... More >> Papageorgiou General Hospital Thessaloniki, Greece, 56403 Less <<
NCT00803712 Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Less << Phase 4 Completed - -
NCT00336739 Healthy Not Applicable Completed - United States, Massachusetts ... More >> Human Nutrition Research Center on Aging at Tufts University Boston, Massachusetts, United States, 02111 Less <<
NCT00113958 End Stage Renal Disease PHASE2 COMPLETED - -
NCT01460030 Parathyroid Carcinoma ... More >> Hypercalcemia Primary Hyperparathyroidism Less << Phase 3 Completed - Japan ... More >> Sendai, Japan Less <<
NCT00975000 Chronic Allograft Nephropathy ... More >> Chronic Kidney Disease Chronic Renal Failure Disordered Mineral Metabolism End Stage Renal Disease Hyperparathyroidism Hypophosphatemia Kidney Disease Kidney Transplantation Post Renal Transplantation Less << Phase 3 Completed - -
NCT01181531 Hyperparathyroidism, Secondary Phase 4 Completed - -
NCT00803712 - Completed - -
NCT00094484 Kidney Disease ... More >> Chronic Kidney Disease Less << Phase 3 Completed - -
NCT01181531 - Completed - -
NCT00936650 Hyperparathyroidism, Primary Phase 2 Completed - -
NCT00975000 - Completed - -
NCT01277510 Chronic Kidney Disease ... More >> Hyperparathyroidism Hyperparathyroidism, Secondary Kidney Disease Secondary Hyperparathyroidism Less << Phase 3 Terminated(Study was suspended... More >> in agreement between sponsor and FDA due to concerns about the study design after a fatality had occurred in the presence of hypocalcemia.) Less << - -
NCT00345839 - Completed - -
NCT01277510 - Terminated(Study was suspended... More >> in agreement between sponsor and FDA due to concerns about the study design after a fatality had occurred in the presence of hypocalcemia.) Less << - -
NCT03027557 Primary Hyperparathyroidism ... More >> Parathyroid Adenoma Parathyroid Hyperplasia Less << Phase 3 Enrolling by invitation March 30, 2019 Denmark ... More >> Aalborg University Hospital Aalborg, Denmark, 9000 Less <<
NCT00952094 Healthy Phase 1 Completed - Korea, Republic of ... More >> Seoul National University Hospital Clinical Trial Center Seoul, Korea, Republic of Less <<
NCT01250405 Chronic Kidney Disease Phase 4 Completed - Canada, Quebec ... More >> Karine Marquis Québec, Quebec, Canada, G1R2J6 Less <<
NCT00977080 Chronic Kidney Disease ... More >> Secondary Hyperparathyroidism Hemodialysis Less << Phase 4 Completed - -
NCT00345839 Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << Phase 3 Completed - -
NCT00928408 Hyperparathyroidism, Primary COMPLETED 2025-02-12 -
NCT00977080 - Completed - -
NCT01054079 Adenocarcinoma of the Prostate... More >> Recurrent Prostate Cancer Less << Phase 2 Completed - United States, North Carolina ... More >> Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 Less <<
NCT00928408 Hyperparathyroidism, Primary COMPLETED 2025-02-12 -
NCT01178450 Secondary Hyperparathyroidism Phase 4 Completed - Spain ... More >> Hospital Universitari de Bellvitge L'Hospitalet de Llobregat, Barcelone, Spain, 08907 Hospital Clinic de Barcelona Barcelona, Spain, 08036 Less <<
NCT00379899 Chronic Kidney Disease ... More >> End Stage Renal Disease Coronary Artery Calcification Vascular Calcification Calcification Cardiovascular Disease Chronic Renal Failure Hyperparathyroidism Kidney Disease Nephrology Secondary Hyperparathyroidism Less << Phase 4 Completed - -
NCT00117052 Secondary Hyperparathyroidism ... More >> End Stage Renal Disease Less << Phase 3 Completed - -
NCT01896232 Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << Phase 3 Completed - -
NCT00379899 - Completed - -
NCT01447368 Kidney Failure ... More >> Secondary Hyperparathyroidism Vascular Diseases Less << Not Applicable Recruiting December 2017 Hong Kong ... More >> Queen Mary Hospital and Tung Wah Hospital Recruiting Hong Kong, Hong Kong, 0000 Contact: Angela YM Wang, MD, PhD    852-22554949    aymwang@hku.hk    Principal Investigator: Angela YM Wang, MD, PhD          Sub-Investigator: Wai-Kei Lo, FRCP Less <<
NCT01896232 - Completed - -
NCT00195936 Hypophosphatemic Rickets, X-Li... More >>nked Dominant Less << PHASE1 COMPLETED 2025-02-08 Section of Pediatric Nephrolog... More >>y, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, 64108, United States Less <<
NCT00975221 Hyperparathyroidism, Primary ... More >> Hypercalcemia Less << Phase 3 Completed - -
NCT00975221 - Completed - -
NCT01101113 Secondary Hyperparathyroidism Phase 4 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Korea, Republic of, 110-744 Kyungpook National University Daegu, Korea, Republic of Gil Hospital Incheon, Korea, Republic of Hallym University Sacred Hospital Pyungchon, Korea, Republic of Seoul National University Bundang Hospital Seongnam, Korea, Republic of Eulji University Seoul, Korea, Republic of Samsung Medical Center Seoul, Korea, Republic of Less <<
NCT03774771 Primary Hyperparathyroidism Phase 2 Completed - -
NCT01054079 - Completed - -
NCT01011114 Hypophosphatemia ... More >> Renal Transplant Less << Not Applicable Unknown - United States, New York ... More >> Montefiore Medical Center Recruiting Bronx, New York, United States, 10467 Principal Investigator: Maria Coco, MD,MS Less <<
NCT00844740 Familial Hypophosphatemic Rick... More >>ets Less << WITHDRAWN 2012-03-01 Children's Mercy Hospital, Kan... More >>sas City, Missouri, 64108, United States Less <<
NCT01103206 Parathyroid Hormone Suppressio... More >>n Test With Cinacalcet Less << Phase 4 Completed - France ... More >> University hospital Rouen, Haute Normandie, France, 76031 Less <<
NCT00936988 Hyperparathyroidism, Primary Phase 2 Completed - -
NCT00431496 Anemia|Secondary Hyperparathyr... More >>oidism Less << PHASE4 COMPLETED 2025-10-09 -
NCT01519037 Relationship Between Calcimime... More >>tic and the RAAS Less << Not Applicable Completed - Switzerland ... More >> CHUV, service de néphrologie/hypertension Lausanne, Vaud, Switzerland, 1011 Less <<
NCT02138838 - Terminated(Sponsor decision) - -
NCT01439867 Chronic Kidney Disease ... More >> Hyperparathyroidism, Secondary Less << Phase 2 Terminated(Sponsor decision) - -
NCT02338934 Secondary Hyperparathyroidism Phase 4 Unknown January 2017 Malaysia ... More >> Clinical Research Centre, Penang Hospital George Town, Penang, Malaysia, 10990 Penang Hospital Not yet recruiting George Town, Penang, Malaysia, 10990 Contact: Ong Loke Meng, FRCS    00 604 2225333 ext 767    onglm@crc.gov.my Less <<
NCT01143987 Hyperparathyroidism|Arterial S... More >>tiffness Less << PHASE4 COMPLETED 2025-02-13 Prince of Wales Hospital, Chin... More >>ese University of Hong Kong, Shatin, New Territories, SAR, Hong Kong Less <<
NCT01439867 - Terminated(Sponsor decision) - -
NCT03776058 Primary Hyperparathyroidism Phase 2 Completed - -
NCT03123406 Hyperparathyroidism; Secondary... More >>, Renal Less << Phase 4 Recruiting September 27, 2019 China, Jiangsu ... More >> Nanjing Jinling Hospital Recruiting Nanjing, Jiangsu, China, 210002 Contact: Zhihong Liu Less <<
NCT02417389 Hyperparathyroidism, Primary ... More >> Osteoporosis Less << Phase 4 Completed - Italy ... More >> Istituto Auxologico Italiano IRCCS Milano, Italy, 20145 Less <<
NCT01290029 Chronic Kidney Disease|Hyperpa... More >>rathyroidism, Secondary|Secondary Hyperparathyroidism Less << PHASE1 COMPLETED 2015-09-23 Research Site, Los Angeles, Ca... More >>lifornia, 90095, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Heidelberg, 69120, Germany|Research Site, Bristol, BS2 8BJ, United Kingdom|Research Site, Glasgow, G3 8SJ, United Kingdom|Research Site, Leeds, LS1 3EX, United Kingdom|Research Site, Manchester, M13 9WL, United Kingdom|Research Site, Nottingham, NG7 2UH, United Kingdom Less <<
NCT01479088 Secondary Hyperparathyroidism Phase 2 Phase 3 Unknown December 2013 Italy ... More >> U.O. Nefrologia e Dialisi- Ospedale Giovanni XXIII Active, not recruiting Bari, Italy, 70100 U.O. Nefrologia e Dialisi - Istituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini Recruiting Genoa, Italy, 16147 Contact: Enrico E Verrina, MD    +390105636276    enricoverrina@ospedale-gaslini.ge.it    Contact: Ornella Della Casa Alberighi, MD PhD    +390105636461    ornelladellacasa@ospedale-gaslini.ge.it    Principal Investigator: Enrico E. Verrina, MD          U.O. Nefrologia e Dialisi Pediatrica - Clinica De Marchi Active, not recruiting Milan, Italy, 20100 U.O. Nefrologia e Dialisi - Ospedale Santobono Active, not recruiting Naples, Italy, 80100 U.O. Nefrologia e Dialisi - Ospedale Bambino Gesù Active, not recruiting Rome, Italy, 00100 Less <<
NCT03299244 Secondary Hyperparathyroidism ... More >> Chronic Kidney Disease Less << Phase 3 Recruiting November 26, 2019 -
NCT02341417 Secondary Hyperparathyroidism,... More >> Chronic Kidney Disease Less << PHASE3 COMPLETED 2017-03-15 Research Site, Los Angeles, Ca... More >>lifornia, 90027, United States|Research Site, Tucker, Georgia, 30084, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Boston, Massachusetts, 02115, United States|Research Site, Minneapolis, Minnesota, 55454, United States|Research Site, Jackson, Mississippi, 39216, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, West Orange, New Jersey, 07052, United States|Research Site, New York, New York, 10029, United States|Research Site, Greenville, North Carolina, 27834, United States|Research Site, Cincinnati, Ohio, 45229, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43205, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Salt Lake City, Utah, 84113, United States|Research Site, Bruxelles, 1020, Belgium|Research Site, Praha 5, 150 06, Czechia|Research Site, Paris, 75015, France|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Marburg, 35043, Germany|Research Site, Athens, 11527, Greece|Research Site, Szeged, 6720, Hungary|Research Site, Genova, 16147, Italy|Research Site, Krakow, 30-663, Poland|Research Site, Lodz, 93-338, Poland|Research Site, Moscow, 107014, Russian Federation|Research Site, Saint Petersburg, 198205, Russian Federation|Research Site, Samara, 443095, Russian Federation|Research Site, Kyiv, 01135, Ukraine Less <<
NCT02341417 Secondary Hyperparathyroidism,... More >> Chronic Kidney Disease Less << PHASE3 COMPLETED 2017-03-15 Research Site, Los Angeles, Ca... More >>lifornia, 90027, United States|Research Site, Tucker, Georgia, 30084, United States|Research Site, Baltimore, Maryland, 21287, United States|Research Site, Boston, Massachusetts, 02115, United States|Research Site, Minneapolis, Minnesota, 55454, United States|Research Site, Jackson, Mississippi, 39216, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Saint Louis, Missouri, 63110, United States|Research Site, West Orange, New Jersey, 07052, United States|Research Site, New York, New York, 10029, United States|Research Site, Greenville, North Carolina, 27834, United States|Research Site, Cincinnati, Ohio, 45229, United States|Research Site, Cleveland, Ohio, 44195, United States|Research Site, Columbus, Ohio, 43205, United States|Research Site, Oklahoma City, Oklahoma, 73104, United States|Research Site, Dallas, Texas, 75235, United States|Research Site, Houston, Texas, 77030, United States|Research Site, Salt Lake City, Utah, 84113, United States|Research Site, Bruxelles, 1020, Belgium|Research Site, Praha 5, 150 06, Czechia|Research Site, Paris, 75015, France|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Marburg, 35043, Germany|Research Site, Athens, 11527, Greece|Research Site, Szeged, 6720, Hungary|Research Site, Genova, 16147, Italy|Research Site, Krakow, 30-663, Poland|Research Site, Lodz, 93-338, Poland|Research Site, Moscow, 107014, Russian Federation|Research Site, Saint Petersburg, 198205, Russian Federation|Research Site, Samara, 443095, Russian Federation|Research Site, Kyiv, 01135, Ukraine Less <<
NCT02138838 Chronic Kidney Disease, Second... More >>ary Hyperparathyroidism Less << Phase 3 Terminated(Sponsor decision) - -
NCT01290029 Chronic Kidney Disease|Hyperpa... More >>rathyroidism, Secondary|Secondary Hyperparathyroidism Less << PHASE1 COMPLETED 2015-09-23 Research Site, Los Angeles, Ca... More >>lifornia, 90095, United States|Research Site, San Francisco, California, 94143, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Kansas City, Missouri, 64108, United States|Research Site, Heidelberg, 69120, Germany|Research Site, Bristol, BS2 8BJ, United Kingdom|Research Site, Glasgow, G3 8SJ, United Kingdom|Research Site, Leeds, LS1 3EX, United Kingdom|Research Site, Manchester, M13 9WL, United Kingdom|Research Site, Nottingham, NG7 2UH, United Kingdom Less <<
NCT00431496 Anemia|Secondary Hyperparathyr... More >>oidism Less << PHASE4 COMPLETED 2025-10-09 -
NCT05926570 Drug Effect PHASE4 COMPLETED 2024-01-22 Sara Mabrouk Mohamed Elghoul, ... More >>Tanta, Egypt Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.80mL

0.56mL

0.28mL

13.99mL

2.80mL

1.40mL

27.98mL

5.60mL

2.80mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Bushinsky DA, Laplante K, et al. Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int. 2006 May;69(9):1586-92.

[2]Colloton M, Shatzen E, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005 Feb;67(2):467-76.

[3]Ma JN, Owens M, Gustafsson M, Jensen J, Tabatabaei A, Schmelzer K, Olsson R, Burstein ES. Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. J Pharmacol Exp Ther. 2011 Apr;337(1):275-84. doi: 10.1124/jpet.110.178194. Epub 2011 Jan 14. PMID: 21239511.

[4]Kawata T, Imanishi Y, Kobayashi K, Onoda N, Okuno S, Takemoto Y, Komo T, Tahara H, Wada M, Nagano N, Ishimura E, Miki T, Ishikawa T, Inaba M, Nishizawa Y. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab. 2006;24(4):300-6. doi: 10.1007/s00774-006-0687-y. PMID: 16816924.

[5]Shalhoub V, Grisanti M, Padagas J, Scully S, Rattan A, Qi M, Varnum B, Vezina C, Lacey D, Martin D. In vitro studies with the calcimimetic, cinacalcet HCl, on normal human adult osteoblastic and osteoclastic cells. Crit Rev Eukaryot Gene Expr. 2003;13(2-4):89-106. doi: 10.1615/critreveukaryotgeneexpr.v13.i24.30. PMID: 14696958.

[6]Imanishi Y, Kawata T, Kenko T, Wada M, Nagano N, Miki T, Arnold A, Inaba M. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism. Calcif Tissue Int. 2011 Jul;89(1):29-35. doi: 10.1007/s00223-011-9490-4. Epub 2011 May 4. PMID: 21541686.

 

Historical Records

Categories